[{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eisai Receives Positive Opinion from EMA\u2019S CHMP on Use of Antiepileptic Agent Fycompa\u00ae in Pediatric Patients","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China NMPA Accepts Eisai\u2019s sNDA for Anti-Epileptic Drug Fycompa as Monotherapy for Partial-Onset Seizures, Paediatric Indication for Partial Onset Seizures","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China NMPA Approves Eisai\u2019s Fycompa as Monotherapy for Partial-Onset Seizures in Patients with Epilepsy 4 Years of Age and Older","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"August 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Eisai","sponsor":"Catalyst Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$160.0 million","newsHeadline":"Catalyst Pharmaceuticals to Acquire U.S. Commercial Rights to FYCOMPA\u00c2\u00ae (Perampanel) CIII From Eisai Co., Ltd","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"December 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Eisai","sponsor":"Catalyst Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$160.0 million","newsHeadline":"Eisai to Divest Rights for Anti-Epileptic Drug Fycompa\u00ae (perampanel) CIII In United States to Catalyst Pharmaceuticals","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"December 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Eisai","sponsor":"Catalyst Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$160.0 million","newsHeadline":"Catalyst Pharmaceuticals Completes the Acquisition of U.S. Rights to FYCOMPA\u00ae (Perampanel) CIII","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"January 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Eisai","sponsor":"Tsukuba Research Laboratories","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Supplementary New Drug Application Submitted in Japan for Antiepileptic Drug Fycompa\u00ae Injection Formulation as A New Route of Administration","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"August 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eisai To Present Latest Data On Fycompa\u00ae (perampanel) Ciii At The 76Th American Epilepsy Society (Aes) Annual Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"November 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eisai to Present Latest Data on Perampanel at The 76th American Epilepsy Society (AES) Annual Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"November 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Akums Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akums gets DCGI Approval for Perampanel Oral Suspension","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"June 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antiepileptic Drug Fycompa\u00ae Injection Formulation Approved in Japan","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"January 2024","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"}]
Find Clinical Drug Pipeline Developments & Deals for Perampanel
Fycompa® (perampanel) is a highly selective, non-competitive AMPA glutamate receptor antagonist. It is indicated for the treatment of partial-onset seizures & primary generalized tonic-clonic seizures in patients with epilepsy 12 years of age and older.
Perampanel oral suspension is first-in-class anti-epileptic agent, With epileptic seizures being mediated by neurotransmitter glutamate, agent is highly selective, noncompetitive AMPA receptor antagonist that reduces neuronal hyperexcitation associated with seizures.
The completion of the acquisition, strengthens the company's Commercial Portfolio with the First and Only AMPA Receptor Antagonist Marketed Product for Epilepsy. Fycompa (perampanel), an oral medication, is a selective non-competitive AMPA receptor antagonist.
Fycompa (perampanel) is a non-competitive AMPA glutamate receptor antagonist used to treat partial-onset seizures with or without secondarily generalized seizures, and as adjunctive treatment of primary generalized tonic-clonic seizures in patients with epilepsy.
Fycompa (perampanel), an oral medication, is a selective non-competitive AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor antagonist.
Perampanel (Fycompa) is first-in-class AED with epileptic seizures being mediated by neurotransmitter glutamate, agent is highly selective, noncompetitive AMPA receptor antagonist reduces neuronal hyperexcitation.
Perampanel is first-in-class anti-epileptic agent, With epileptic seizures being mediated by neurotransmitter glutamate, agent is highly selective, noncompetitive AMPA receptor antagonist that reduces neuronal hyperexcitation associated with seizures.
Fycompa is a first-in-class AED discovered at Eisai’s Tsukuba Research Laboratories. The agent is a highly selective, noncompetitive AMPA receptor antagonist that is postulated to reduce neuronal hyper-excitation associated with seizures.
Fycompa has already been approved in China as an adjunctive treatment for partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy 12 years of age and older.
The submission covering partial-onset seizures in pediatric patients was based on the results of a Phase III study of Fycompa as an adjunctive therapy conducted globally on pediatric patients with uncontrolled partial onset seizures/primary generalized tonic-clonic seizures.